Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Alector Inc (ALEC) USD0.0001

Sell:$33.04 Buy:$33.10 Change: $1.49 (4.71%)
Market closed |  Prices as at close on 22 May 2020 | Switch to live prices |
Change: $1.49 (4.71%)
Market closed |  Prices as at close on 22 May 2020 | Switch to live prices |
Change: $1.49 (4.71%)
Market closed |  Prices as at close on 22 May 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL101, Al002 and AL003. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).

Contact details

151 Oyster Point Blvd Ste 300
United States
+1 (415) 2315660

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.62 billion
Shares in issue:
79.03 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Tillman Gerngross
    Chairman of the Board, Co-Founder
  • Shehnaaz Suliman
    President, Chief Operating Officer
  • Arnon Rosenthal
    Chief Executive Officer, Co-Founder, Director
  • Calvin Yu
    Vice President - Finance
  • Robert King
    Chief Development Officer
  • Sabah Oney
    Chief Business Officer
  • Robert Paul
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.